New Risk • Jul 03
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$14.1m (US$9.93m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.8m free cash flow). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (CA$419k revenue, or US$295k). Market cap is less than US$10m (CA$14.1m market cap, or US$9.93m). Minor Risk Shareholders have been diluted in the past year (21% increase in shares outstanding). Reported Earnings • Jul 02
Third quarter 2026 earnings released: CA$0.005 loss per share (vs CA$0.011 loss in 3Q 2025) Third quarter 2026 results: CA$0.005 loss per share (improved from CA$0.011 loss in 3Q 2025). Net loss: CA$1.08m (loss narrowed 37% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. New Risk • Apr 16
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.6m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 24% per year over the past 5 years. Revenue is less than US$1m (CA$317k revenue, or US$231k). Minor Risks Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (CA$30.6m market cap, or US$22.3m). Reported Earnings • Apr 04
Second quarter 2026 earnings released: CA$0.008 loss per share (vs CA$0.011 loss in 2Q 2025) Second quarter 2026 results: CA$0.008 loss per share (improved from CA$0.011 loss in 2Q 2025). Net loss: CA$1.35m (loss narrowed 27% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Tillkännagivande • Mar 05
KDA Group Inc., Annual General Meeting, Apr 29, 2026 KDA Group Inc., Annual General Meeting, Apr 29, 2026. Location: quebec, quebec city Canada New Risk • Feb 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 16% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.2m free cash flow). Earnings have declined by 27% per year over the past 5 years. Revenue is less than US$1m (CA$252k revenue, or US$185k). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (CA$34.3m market cap, or US$25.2m). Reported Earnings • Jan 01
First quarter 2026 earnings released: CA$0.008 loss per share (vs CA$0.014 loss in 1Q 2025) First quarter 2026 results: CA$0.008 loss per share (improved from CA$0.014 loss in 1Q 2025). Net loss: CA$1.31m (loss narrowed 40% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 30
Full year 2025 earnings released: CA$0.047 loss per share (vs CA$0.04 loss in FY 2024) Full year 2025 results: CA$0.047 loss per share (further deteriorated from CA$0.04 loss in FY 2024). Net loss: CA$8.05m (loss widened 21% from FY 2024). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jun 30
Third quarter 2025 earnings released: CA$0.011 loss per share (vs CA$0.012 loss in 3Q 2024) Third quarter 2025 results: CA$0.011 loss per share (improved from CA$0.012 loss in 3Q 2024). Net loss: CA$1.72m (loss narrowed 18% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • May 30
KDA Group Inc. announced that it has received CAD 2.2 million in funding KDA Group Inc announced a private placement to issue 8,800,000 units at a price of CAD 0.25 per Unit for total gross proceeds of CAD 2,200,000 on May 29, 2025. Each Unit consists of one Class A Share and one Common share purchase warrant. Each Warrant entitles the holder to purchase one additional Common share of the Corporation at an exercise price of CAD 0.35 per Common share for a period of 24 months ending May 29, 2027. All securities issued pursuant to the Private Placement are subject to a mandatory four-month and one day hold period expiring on September 30, 2025 in accordance with applicable securities regulations. The transaction included participation from accredited investors. The Private Placement was carried out pursuant to prospectus exemptions of applicable securities laws and is subject to final acceptance by the TSX Venture Exchange. Insider, Marc Lemieux purchased 80,000 Units for a total consideration of CAD 20,000. Marc Lemieux is hereinafter referred to as the “Insider”. No finder’s fee nor commission are payable in connection with the Private Placement. Tillkännagivande • May 22
KDA Group Inc. Receives DSQ Certification for Adherize+ Platform KDA Group Inc. announced that its Adherize+ platform, designed to optimize patient follow-up and care coordination, has officially received certification from Dossier Sante Quebec ("DSQ"). This authorization marks a major step toward full production deployment. At the core of Adherize+ is Medherize, a high-impact specialized module developed to support interdisciplinary follow-up for patients undergoing targeted cancer therapies. Leveraging structured, real-time data exchange through granular integration, a first in Quebec, Medherize brings significant value to healthcare operations and outcomes, positioning it as a key strategic asset within the Adherize+ ecosystem for the entire Quebec population. With this certification secured, the pilot project at Hopital Saint-Sacrement in Quebec City is set to begin, marking the start of a phased rollout to other healthcare institutions across the province. As more specialty therapies are delivered orally and managed outside of hospitals by community pharmacies, the need for robust digital tools like Medherize are becoming essential for physicians, pharmacists, and nursing staff. These high-cost treatments are often associated with significant adverse effects and adherence challenges. Ensuring appropriate monitoring can directly impact patient survival and reduce systemic risks. Medherize is designed to meet this growing need, improving continuity of care for patients whose lives depend on strict therapeutic management. Tillkännagivande • Apr 16
KDA Group Inc. Reaches Final Certification Phase for Medherize with Dossier Sante Quebec KDA Group Inc. announced that it has reached the final phase in the certification process for its Medherize platform's integration with the Dossier Sante Quebec ("DSQ"). Following the successful completion of the initial certification phase announced on December 3, 2024, all three required development phases for the module have now been completed. On April 7, 2025, the Direction des produces de prestations de services du DSQ, through its Integration and Certification Support Team, confirmed that the final self-assessment phase was successfully passed. The final audit is scheduled for April 22-24, 2025, marking the last technical validation before full integration. The initial deployment of Medherize is planned for May 5, 2025, at the St-Sacrement Hospital Center in Quebec City, followed by a progressive rollout across other healthcare institutions in the province. KDA is now the first technology provider in Quebec to successfully certify for DSQ integration using the granular data mode--a major advancement in the transmission of clinical information. Unlike laboratory results delivered in PDF format, which are often static and difficult to process, the granular mode enables structured, interoperable, and seamlessly integrable data within clinical systems. This model provides substantial gains in efficiency, safety, quality of care, as well as reductions in delays and human error. Reported Earnings • Mar 16
Second quarter 2025 earnings released: CA$0.011 loss per share (vs CA$0.008 loss in 2Q 2024) Second quarter 2025 results: CA$0.011 loss per share (further deteriorated from CA$0.008 loss in 2Q 2024). Net loss: CA$1.85m (loss widened 52% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Feb 25
KDA Group Inc. Approves the Appointment of Jean-Marc Léveillé as Members of the Audit Committee KDA Group Inc. at its annual general meeting of shareholders held on February 20, 2025 approved the appointment of Jean-Marc Léveillé as members of the Corporation's audit committee. New Risk • Jan 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.0m free cash flow). Revenue is less than US$1m (CA$152k revenue, or US$106k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Market cap is less than US$100m (CA$46.8m market cap, or US$32.7m). Reported Earnings • Dec 29
First quarter 2025 earnings released: CA$0.014 loss per share (vs CA$0.01 loss in 1Q 2024) First quarter 2025 results: CA$0.014 loss per share (further deteriorated from CA$0.01 loss in 1Q 2024). Net loss: CA$2.20m (loss widened 46% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Dec 24
KDA Group Inc., Annual General Meeting, Feb 20, 2025 KDA Group Inc., Annual General Meeting, Feb 20, 2025. Location: quebec, quebec Canada New Risk • Sep 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$5.7m free cash flow). Revenue is less than US$1m (CA$204k revenue, or US$151k). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (9.7% increase in shares outstanding). Market cap is less than US$100m (CA$44.8m market cap, or US$33.1m). New Risk • Jun 23
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$5.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$5.7m free cash flow). Revenue is less than US$1m (CA$204k revenue, or US$149k). Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CA$51.7m market cap, or US$37.8m). Tillkännagivande • Jun 13
KDA Group Inc. Announces the Development of Medherize, A New Clinical Management Solution for Specialized Medics for Breast Cancer KDA Group Inc. announced the launch of Medherize, its revolutionary new platform dedicated to the clinical management of patients requiring specialized medications. This pioneering project particularly focuses on CDK 4/6 inhibitors used in the treatment of breast cancer, with the objective of ensuring optimal and personalized patient follow-up. Medherize marks the first collaboration among specialist doctors, pharmacists and patients to offer integrated and coordinated care. KDA's new clinical management solution is designed to address the complex challenges associated with the administration of CDK 4/6 inhibitors, essential medications in the treatment of certain types of breast cancer. This innovative technology offers an integrated platform enabling healthcare professionals to accurately monitor patient treatments, track side effects and adjust doses in real-time while ensuring seamless communication between patients and care providers. Key Features of Medherize: Personalized Patient Follow-Up: An intuitive user interface allowing doctors to personalize and track treatment plans for each patient, ensuring better adherence to prescribed therapies. Real-Time Monitoring: Integration of monitoring devices that collect real-time data on patients' health status, enabling rapid intervention when needed. Side Effect Management: A proactive notification system to monitor and manage potential side effects of CDK 4/6 inhibitor. Optimized Communication: A secure communication platform facilitating exchanges between patients, doctors and pharmacists, thereby enhancing care coordination. Analysis and Reporting. Advanced analytical tools to generate detailed reports on treatment effectiveness, supporting evidence-based clinical decision-making. This pilot project, the first of its kind, will be deployed in the Corporation's partner clinics and hospitals in the coming months, with ambitions to expand internationally. KDA remains committed to investing in innovation and closely collaborating with healthcare professionals to continue developing cutting-edge solutions that meet the evolving needs of the healthcare sector. Artificial intelligence and new technologies could reduce healthcare spending by $200 to $360 billion. New Risk • Mar 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$5.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$5.0m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CA$70.1m market cap, or US$51.8m). Tillkännagivande • Mar 16
KDA Group Inc., Annual General Meeting, May 16, 2024 KDA Group Inc., Annual General Meeting, May 16, 2024. Tillkännagivande • Dec 09
KDA Group Inc. announced that it has received CAD 1.125 million in funding KDA Group Inc. announced a private placement to issue 11,250,000 units at an issue price of CAD 0.10 per unit for the gross proceeds of CAD 1.250,000 on December 8, 2023. Each Unit consists of one Class A Share and one Common share purchase warrant. Each Warrant entitles the holder to purchase one additional Common share of the Corporation at an exercise price of CAD 0.15 per Common share for a period of 24 months ending December 8, 2025. The transaction included participation from accredited investors. All securities issued pursuant to the Private Placement are subject to a mandatory four-month and one day hold period expiring on April 9, 2024 in accordance with applicable securities regulations. No finder’s fee nor commission are payable in connection with the Private Placement. The Private Placement was carried out pursuant to prospectus exemptions of applicable securities laws and is subject to final acceptance by the TSX Venture Exchange. Reported Earnings • Dec 01
Full year 2023 earnings released: EPS: CA$0.004 (vs CA$0.031 loss in FY 2022) Full year 2023 results: EPS: CA$0.004 (up from CA$0.031 loss in FY 2022). Net income: CA$618.4k (up CA$5.18m from FY 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Tillkännagivande • Sep 06
KDA Group Inc. Announces Executive Changes KDA Group Inc. announced the appointment of Mr. Michael W. Kinley as Chief Financial Officer of the Corporation, effective September 1, 2023, following the departure of Mr. Luc Olivier. Mr. Kinley is a Chartered Professional Accountant with extensive public company experience and serves as Director and Chairman of the Corporations Audit Committee since January 2015. He has previously acted as the Corporations interim Chief Financial Officer. With his skills, experience and knowledge of the Corporations activities, Mr. Kinley will be able to efficiently assist the Corporation. New Risk • Jul 31
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$766k free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Shareholders have been diluted in the past year (8.0% increase in shares outstanding). Market cap is less than US$100m (CA$13.6m market cap, or US$10.3m). New Risk • Jul 10
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$766k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$766k free cash flow). Market cap is less than US$10m (CA$11.2m market cap, or US$8.47m). Minor Risk Share price has been volatile over the past 3 months (16% average weekly change). New Risk • Jul 08
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -CA$796k This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (CA$10.5m market cap, or US$7.91m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-CA$796k). Share price has been volatile over the past 3 months (16% average weekly change). Reported Earnings • Jul 07
Third quarter 2023 earnings released Third quarter 2023 results: Net loss: CA$1.09m (loss narrowed 34% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Tillkännagivande • Jun 30
KDA Group Inc. Announces Directors Resignation KDA Group Inc. announced the total repayment, as of June 28, 2023, of its debts owed to Persistence Capital Partners II, L.P. and Persistence Capital Partners II (International), L.P., (collectively PCP) and to Private Debt Partners Senior Opportunities Fund LP (PDP). Following the full repayment of PCPs debt by KDA, PCPs representatives, Messrs. Joshua Chandler and David Lampron, resigned from the board of directors of the Corporation (the Board of Directors), effective June 28, 2023. Therefore, the Board of Directors is now comprised of Ms. Isabelle Bgin, Messrs. Patrick Fernet, Michael W. Kinley and Marc Lemieux. Tillkännagivande • Jun 29
KDA Group Inc. (TSXV:KDA) entered into an agreement to acquire right, title and interest in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million. KDA Group Inc. (TSXV:KDA) entered into an agreement to acquire right, title and interest in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million on June 27, 2023. The consideration will be paid through the issuance of 10,000,000 Class A shares in the share capital of KDA Group. ZoomMed Board of Directors has unanimously approved an agreement for the sale. The transaction will be completed following the satisfaction or waiver of all closing conditions provided for in the asset purchase agreement, including the approval by the shareholders of the ZoomMed and obtaining the approvals from applicable regulatory authorities. Tillkännagivande • May 30
9486-4410 Quebec Inc entered into a share purchase agreement to acquire Agence L.I.V. Inc. from KDA Group Inc. (TSXV:KDA) for $13.5 million. 9486-4410 Quebec Inc entered into a share purchase agreement to acquire Agence L.I.V. Inc. from KDA Group Inc. (TSXV:KDA) for $13.5 million on May 26, 2023. The Sale Price is payable by the payment of $12.29 million at the closing of the transaction, and an escrow amount of $1.21 million for a period of twelve months to secure the adjustments to the Sale Price and the indemnification undertakings set forth in the Share Purchase Agreement.The transaction is subject to the satisfaction of certain conditions including the approval of the TSX Venture Exchange, the consent of KDA’s creditors, Persistence Capital Partners II, L.P. and Private Debt Partners Senior Opportunities Fund LP, and the consent of KDA’s shareholders. The consent of KDA’s shareholders will be sought at the annual general and special meeting of the Corporation’s shareholders to be held on Tuesday, June 27, 2023. In connection with the transaction, KDA and the Purchaser are arm’s length parties and a finder’s fees totalling$336,000will be payable to an arm's length party, the whole subject to the closing of the transaction and approval by the TSXV. The proposed transaction is expected to close on or about June 30, 2023. Reported Earnings • Mar 25
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: CA$8.37m (up 25% from 2Q 2022). Net loss: CA$33.7k (loss narrowed 96% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Tillkännagivande • Dec 22
KDA Group Inc. (TSXV:KDA) acquired Covapharm Inc. KDA Group Inc. (TSXV:KDA) agree to acquire Covapharm Inc on December 16, 2022. consideration of CAD 200,000.00 payable in monthly instalments of CAD10,000.00 over a period of twenty months from the closing date and a maximum of 1,825,000 Class A shares in the capital stock of the Corporation. The issuance of the KDA Shares is subject to the approval of the TSX Venture Exchange. Mr. Côté will become a consultant to KDA.
KDA Group Inc. (TSXV:KDA) acquired Covapharm Inc on December 21, 2022. Reported Earnings • Nov 26
Full year 2022 earnings released: CA$0.03 loss per share (vs CA$0.007 profit in FY 2021) Full year 2022 results: CA$0.03 loss per share (down from CA$0.007 profit in FY 2021). Revenue: CA$28.8m (up 18% from FY 2021). Net loss: CA$4.56m (down CA$5.45m from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Board Change • Nov 18
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. Co-Founder, Executive VP of Pharmacy Services Division & Director Isabelle Begin is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Oct 19
KDA Group Inc. Appoints Luc Olivier as Chief Financial Officer KDA Group Inc. announced the appointment of Mr. Luc Olivier as Chief Financial Officer of the Corporation effective October 17, 2022. As a result of this appointment, Mr. Michael W. Kinley, who has been acting as interim Chief Financial Officer of the Corporation, will remain a director of the Corporation. Luc Olivier Mr. Olivier is a Chartered Professional Accountant (CPA) recognized as a corporate financial management strategist, who distinguishes himself by his ability to understand critical business issues, from a financial and operational point of view, in order to implement adapted, concrete and feasible solutions. His success is based on his ability to serve each of the Corporations internal customers, namely procurement, operations, logistics, sales, marketing and human resources, with quality financial data for informed decision making and to provide management with comprehensive, global analyses for decision making based on sound assumptions. As the person responsible for finance, accounting and information technology for more than 30 years in public and private companies established in Quebec with national and international exposure, he has completed several projects that have had a marked impact on the success and sustainability of organizations. Tillkännagivande • Jul 30
KDA Group Inc. Announces Executive Changes KDA Group Inc. announced the departure of Mr. Pierre Monet as Chief Financial Officer of the Corporation effective immediately. The Corporation also announces the appointment of Mr. Michael W. Kinley as interim Chief Financial Officer of the Corporation who will assume the duties of Chief Financial Officer effective immediately. Mr. Kinley is a Chartered Professional Accountant with extensive experience of public companies and serves as Director of theCorporation since January 2015. He has previously acted as interim Chief Financial Officer of the Corporation.With his skills, experience and knowledge of the Corporations activities, Mr. Kinley will be able to assist theCorporation efficiently. Reported Earnings • Jun 24
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: CA$7.07m (up 18% from 3Q 2021). Net loss: CA$1.66m (loss widened 129% from 3Q 2021). Board Change • May 03
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. Co-Founder, Executive VP of Pharmacy Services Division & Director Isabelle Begin is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Mar 06
KDA Group Inc., Annual General Meeting, Apr 27, 2022 KDA Group Inc., Annual General Meeting, Apr 27, 2022. Location: Boucherville, QC Boucherville Quebec Canada Reported Earnings • Dec 01
Full year 2021 earnings: Revenues in line with analyst expectations Full year 2021 results: Revenue: CA$24.4m (up 6.4% from FY 2020). Net income: CA$885.3k (up CA$5.20m from FY 2020). Profit margin: 3.6% (up from net loss in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Executive Departure • Sep 17
Chief Executive Officer Sylvain Duvernay has left the company On the 14th of September, Sylvain Duvernay's tenure as Chief Executive Officer of the company ended after less than a year in the role. As of June 2021, Sylvain still personally held 824.00k shares (CA$115k worth at the time). Sylvain is the only executive to leave the company over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Under Sylvain's leadership, the company delivered a total shareholder return of 17%. Reported Earnings • Jul 01
Third quarter 2021 earnings released: CA$0.006 loss per share (vs CA$0.002 loss in 3Q 2020) The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: CA$5.99m (up 10.0% from 3Q 2020). Net loss: CA$723.6k (loss widened 231% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 20
Second quarter 2021 earnings released The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: CA$5.95m (down 4.4% from 2Q 2020). Net income: CA$220.5k (up CA$338.1k from 2Q 2020). Profit margin: 3.7% (up from net loss in 2Q 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 22% per year whereas the company’s share price has increased by 17% per year. Is New 90 Day High Low • Feb 27
New 90-day high: CA$0.20 The company is up 17% from its price of CA$0.17 on 27 November 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 6.0% over the same period. Tillkännagivande • Dec 23
An unknown buyer entered into letter of intent to acquire 51% stake in CanNorth Medic Inc. from KDA Group Inc. (TSXV:KDA) for CAD 2.4 million. An unknown buyer entered into letter of intent to acquire 51% stake in CanNorth Medic Inc. from KDA Group Inc. (TSXV:KDA) for CAD 2.4 million on November 20, 2020. Tillkännagivande • Dec 05
KDA Group Inc., Annual General Meeting, Jan 29, 2021 KDA Group Inc., Annual General Meeting, Jan 29, 2021. Reported Earnings • Dec 03
Full year 2020 earnings released: CA$0.04 loss per share The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were flat. Full year 2020 results: Revenue: CA$22.9m (flat on FY 2019). Net loss: CA$4.31m (loss narrowed 46% from FY 2019). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Nov 27
KDA Group Inc. announced that it has received CAD 1.2 million in funding KDA Group Inc. (TSXV: KDA) announced a private placement with accredited investors for 8,000,000 units at a price of CAD 0.15 per unit for gross proceeds of CAD 1,200,000 on November 25, 2020. Each unit consists of one class A shares and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at an exercise price of CAD 0.20 per share for a period of 12 months from the date of closing. The transaction is subject to approval from TSX Venture Exchange. The corporation paid a cash commission of CAD 10,132.50 in relation to this private placement and issued 67,550 non-transferable share purchase warrants. Each broker warrant entitles the holder to purchase one common share at an exercise price of CAD 0.15 per common share for a period of 12 months ending November 24, 2021. All securities issued in connection with the private placement are subject to a mandatory four-month hold period expiring on March 25, 2021 in accordance with applicable securities regulations. Is New 90 Day High Low • Nov 24
New 90-day high: CA$0.22 The company is up 76% from its price of CA$0.13 on 25 August 2020. The Canadian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 11% over the same period. 
